8-K: Passage Bio Transfers Listing to Nasdaq Capital Market, Granted Extension to Regain Compliance

Passage Bio, Inc. has transferred its stock listing to the Nasdaq Capital Market and received an extension until July 28, 2025, to regain compliance with the minimum bid price requirement.

Summary

• Passage Bio, Inc. received notification from Nasdaq on August 1, 2024, that it was not in compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive business days.
• The company applied to transfer its listing from The Nasdaq Global Select Market to The Nasdaq Capital Market.
• On January 29, 2025, Nasdaq approved the transfer, which took effect on January 30, 2025.
• The company's shares will continue to trade under the symbol PASG.
• As a result of the transfer, Passage Bio was granted an additional 180 days, until July 28, 2025, to regain compliance with the minimum bid price requirement.
• To regain compliance, the closing bid price of the company's shares must meet or exceed $1.00 for at least 10 consecutive business days by July 28, 2025.
• The company intends to monitor the minimum bid price and consider options to resolve any deficiencies, including a reverse stock split if necessary.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company received an extension, it also had to transfer to a lower-tier market, indicating underlying financial challenges.

Positives

• Nasdaq approved Passage Bio's request to transfer to The Nasdaq Capital Market.
• Passage Bio received an additional 180 days to regain compliance with the minimum bid price requirement.
• The company is considering options to resolve the deficiency, including a reverse stock split.

Negatives

• Passage Bio was not in compliance with Nasdaq's minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive business days.
• The company had to transfer its listing to The Nasdaq Capital Market.

Risks

• There is a risk that Passage Bio will not be able to regain compliance with the minimum bid price requirement by July 28, 2025.
• The company may need to implement a reverse stock split, which could negatively impact shareholders.

Future Outlook

Passage Bio intends to actively monitor the minimum bid price requirement and consider available options to resolve any deficiencies and regain compliance.

Industry Context

Many small-cap biotech companies face challenges in maintaining share price compliance, especially during periods of market volatility or when clinical trial results are delayed or disappointing. Transferring to the Nasdaq Capital Market provides additional time for companies to improve their financial position and regain compliance.

Comparison to Industry Standards

• Many companies in the biotech sector have faced similar challenges with maintaining Nasdaq listing requirements.
• Companies like XOMA Corporation have previously executed reverse stock splits to regain compliance.
• The Nasdaq Capital Market provides a venue for smaller companies to continue trading while addressing compliance issues, similar to the NYSE American exchange.

Stakeholder Impact

• Shareholders may experience dilution if a reverse stock split is implemented.
• Employees may be affected by cost-cutting measures if the company struggles to regain compliance.
• The company's ability to raise capital could be impacted if it is not listed on a major exchange.

Next Steps

• Passage Bio will continue to monitor its stock price.
• Passage Bio will consider options to regain compliance with the minimum bid price requirement, including a potential reverse stock split.

Key Dates